Linguamatics, the leader in natural language processing (NLP)-based text mining, announced that the Federal Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has licensed its 12E text mining platform as a discovery and decision support tool to supplement laboratory research efforts on drug safety. The FDA will use the platform to review published literature and drug product labels to address key biomedical issues, including mechanisms of drug toxicity and disease processes. العب بلاك جاك اون لاين In addition to document retrieval, the 12E platform can identify, extract, synthesize, and analyze relevant facts and relationships (e. لعب بينجو g., between genes and diseases, drugs and side effects). موقع مراهنات Customers include top tier commercial, academic, and governmental organizations, including 9 of the top 10 global pharmaceutical companies. The 12E platform is available both as an in-house or cloud-based system.
Typical applications in pharmaceutical, biotechnology, and healthcare include:
• Mapping gene-disease relationships and identifying potentially novel therapeutic targets
• Biomarker discovery
• Drug repurposing
• Drug safety
• Patent analysis
• Clinical trial site selection and study design
• Mining electronic medical records to improve prediction of health outcomes
• Translational medicine
• Competitive intelligence
• Social media mining
• Subjective data mining (sentiment analysis, key opinion mining)
Sources: BioSpace and Business Weekly